Business Description
OBI Pharma Inc
ISIN : TW0004174008
Total Employee Number:
40Description
OBI Pharma Inc is engaged in the research and development of novel therapeutic agents and biologics for patients with unmet medical needs. The company has three reportable segments: the anti-cancer new drug segment, the botulinum toxin new drug segment, and the CDMO segment. Geographically, it generates the majority of its revenue from Taiwan.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.3 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.27 | |||||
Debt-to-EBITDA | -0.26 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -1.82 | |||||
Beneish M-Score | -0.75 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 119.6 | |||||
3-Year EBITDA Growth Rate | -1 | |||||
3-Year EPS without NRI Growth Rate | -29.3 | |||||
3-Year FCF Growth Rate | 2.9 | |||||
3-Year Book Growth Rate | -29.1 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.95 | |||||
9-Day RSI | 41.88 | |||||
14-Day RSI | 43.93 | |||||
3-1 Month Momentum % | -25.37 | |||||
6-1 Month Momentum % | -46.48 | |||||
12-1 Month Momentum % | -56.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.51 | |||||
Quick Ratio | 4.45 | |||||
Cash Ratio | 3.38 | |||||
Days Inventory | 70.19 | |||||
Days Sales Outstanding | 34.46 | |||||
Days Payable | 5.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.6 | |||||
Shareholder Yield % | -1.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -132.36 | |||||
Operating Margin % | -3702.58 | |||||
Net Margin % | -3504.61 | |||||
EBITDA Margin % | -3447.18 | |||||
FCF Margin % | -3531.21 | |||||
OCF Margin % | -3448.8 | |||||
ROE % | -74.18 | |||||
ROA % | -46.4 | |||||
ROIC % | -95.37 | |||||
3-Year ROIIC % | -15.69 | |||||
ROC (Joel Greenblatt) % | -189.98 | |||||
ROCE % | -55.01 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 2.74 | |||||
PS Ratio | 63.82 | |||||
PB Ratio | 1.97 | |||||
Price-to-Tangible-Book | 2.03 | |||||
EV-to-EBIT | -1.74 | |||||
EV-to-EBITDA | -1.93 | |||||
EV-to-Revenue | 66.62 | |||||
EV-to-FCF | -2 | |||||
Price-to-GF-Value | 0.2 | |||||
| Price-to-Net-Current-Asset-Value | 78.89 | |||||
Earnings Yield (Greenblatt) % | -57.65 | |||||
FCF Yield % | -55.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OBI Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 58.575 | ||
| EPS (TTM) (NT$) | -15.608 | ||
| Beta | 0.6892 | ||
| 3-Year Sharpe Ratio | -1.31 | ||
| 3-Year Sortino Ratio | -1.59 | ||
| Volatility % | 33.96 | ||
| 14-Day RSI | 43.93 | ||
| 14-Day ATR (NT$) | 1.204583 | ||
| 20-Day SMA (NT$) | 28.96 | ||
| 12-1 Month Momentum % | -56.84 | ||
| 52-Week Range (NT$) | 26.45 - 73.2 | ||
| Shares Outstanding (Mil) | 131.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OBI Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OBI Pharma Inc Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| 0.5:1 Stock Split | 2026-01-27 | 55.20 (+4.35%) |
Show
Entries
OBI Pharma Inc Frequently Asked Questions
What is OBI Pharma Inc(ROCO:4174)'s stock price today?
The current price of ROCO:4174 is NT$28.40. The 52 week high of ROCO:4174 is NT$73.20 and 52 week low is NT$26.45.
When is next earnings date of OBI Pharma Inc(ROCO:4174)?
The next earnings date of OBI Pharma Inc(ROCO:4174) is .
Does OBI Pharma Inc(ROCO:4174) pay dividends? If so, how much?
OBI Pharma Inc(ROCO:4174) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on OBI Pharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers